{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Lymphomas&page=21", "query": { "condition": "Relapsed/Refractory Lymphomas", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 1805, "total_pages": 181, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Lymphomas&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Lymphomas&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T09:04:20.265Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00211276", "title": "A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "ONTAK (denileukin diftitox)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2005-03", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2012-03-14", "last_synced_at": "2026-11-14T09:04:20.265Z", "location_count": 12, "location_summary": "Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 9 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00211276" }, { "nct_id": "NCT03947255", "title": "A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma", "Peripheral T Cell Lymphoma", "Anaplastic Large Cell Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-10-28", "completion_date": "2022-11-06", "has_results": true, "last_update_posted_date": "2023-10-13", "last_synced_at": "2026-11-14T09:04:20.265Z", "location_count": 19, "location_summary": "Anaheim, California • Lafayette, Colorado • Pembroke Pines, Florida + 14 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Lafayette", "state": "Colorado" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Elk Grove Village", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03947255" }, { "nct_id": "NCT00006125", "title": "Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "2000-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-11-14T09:04:20.265Z", "location_count": 75, "location_summary": "Anniston, Alabama • La Jolla, California • San Diego, California + 54 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006125" }, { "nct_id": "NCT03445858", "title": "Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Childhood Solid Tumor", "Childhood Lymphoma", "Relapsed Cancer", "Refractory Cancer", "Adult Solid Tumor", "Adult Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Hypofractionated Index Site Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "40 Years", "sex": "ALL", "summary": "12 Months to 40 Years" }, "enrollment_count": 22, "start_date": "2018-02-12", "completion_date": "2023-11-07", "has_results": false, "last_update_posted_date": "2026-02-18", "last_synced_at": "2026-11-14T09:04:20.265Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03445858" }, { "nct_id": "NCT02605694", "title": "Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Duvelisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "R-CHOP", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SecuraBio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-12", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2021-03-17", "last_synced_at": "2026-11-14T09:04:20.265Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605694" }, { "nct_id": "NCT00081861", "title": "Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Avastin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2004-03", "completion_date": "2007-09", "has_results": true, "last_update_posted_date": "2012-04-05", "last_synced_at": "2026-11-14T09:04:20.265Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081861" }, { "nct_id": "NCT00002980", "title": "Decitabine in Treating Patients With Melanoma or Other Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Cancer Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-11-14T09:04:20.265Z", "location_count": 4, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002980" }, { "nct_id": "NCT03384654", "title": "A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Precursor Cell Lymphoblastic Leukemia-Lymphoma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Peg-asparaginase", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "6-mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 47, "start_date": "2018-05-14", "completion_date": "2022-09-27", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-11-14T09:04:20.265Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03384654" }, { "nct_id": "NCT03019666", "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Non-Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "Mantle-Cell Lymphoma", "Follicular Lymphoma", "Indolent B Cell Lymphoma", "Primary Mediastinal Lymphoma", "Lymphoplasmacytic Lymphoma" ], "interventions": [ { "name": "Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 39, "start_date": "2017-10-18", "completion_date": "2022-08-15", "has_results": false, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-11-14T09:04:20.265Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03019666" }, { "nct_id": "NCT01421667", "title": "A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, B-Cell", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Non-Hodgkin", "Lymphoma, T-Cell" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 176, "start_date": "2011-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-11-28", "last_synced_at": "2026-11-14T09:04:20.265Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Duarte, California • Oxnard, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01421667" } ] }